Skip to main content

Advertisement

SpringerLink
Log in

Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique

  • Original Article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

The presence of circulating antineuronal antibodies has been associated with paraneoplastic neurological syndromes (PNS). Ri antibodies are often associated with lung or breast cancer, but the prevalence of such antibodies in large cancer materials is largely unknown. We used a highly sensitive immunoprecipitation assay to study the level of Ri antibodies in blood samples from 200 patients with small cell lung cancer (SCLC), 253 patients with breast cancer and 557 patients with ovarian cancer. Two hundred blood donors and six Ri positive PNS patients served as controls. The recombinant antigen used in the immunoprecipitation assay was radiolabeled by a coupled in vitro transcription and translation (ITT) technique, enabling low levels of antibodies to be detected. None of the blood donors contained Ri antibodies, whereas all of the sera from the PNS patients were positive. Ri antibodies were present in 4.5% of the patients with SCLC, 0.8% of the patients with breast cancer and in 0.2% of the patients with ovarian cancer. Retesting of the Ri positive samples with immunofluorescense and immune blot showed that the immunoprecipitation technique was more sensitive than the other immune assays. Ri antibodies were not associated with PNS in the patients with breast or ovarian cancer. Neurological data were not available for the SCLC patients, but in these, Ri antibodies were not associated with survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554

    Article  PubMed  CAS  Google Scholar 

  2. Vincent A (1999) Antibodies to ion channels in paraneoplastic disorders. Brain Pathol 9:285–291

    Article  PubMed  CAS  Google Scholar 

  3. Scaravilli F, Shu FA, Groves M., Thom M (1999) The neuropathology of paraneoplastic syndromes. Brain Pathol 9:251–260

    Article  PubMed  CAS  Google Scholar 

  4. Musunuru K, Darnell RB (2001) Paraneoplastic neurologic disease antigens: RNA-binding proteins and signaling proteins in neuronal degeneration. Annu Rev Neurosci 24:239–262

    Article  PubMed  CAS  Google Scholar 

  5. Pittock SJ, Lucchinetti CF, Lennon VA (2003) Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol 53:580–587

    Article  PubMed  CAS  Google Scholar 

  6. Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka- Setinek U, Marzorati L, Wondrusch E, Cavaletti G (1997) Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 244:85–89

    Article  PubMed  CAS  Google Scholar 

  7. Jongen JL, Moll WJ, Sillevis Smitt PA, Vecht CJ, Tijssen CC (1998) Anti-Ri positive opsoclonus-myoclonus-araxia in ovarian duct cancer. J Neurol 245:691–692

    Article  PubMed  CAS  Google Scholar 

  8. Kikuchi H, Yamada T, Okayama A, Hara H, Taniwaki T, Shigeto H, Sasaki M, Iwaki T, Kira J (2000) Anti-Ri-associated paraneoplastic cerebellar degeneration without opsoclonus in a patient with a neuroendocrine carcinoma of the stomach. Fukuoka Igaku Zasshi 91:104–109

    PubMed  CAS  Google Scholar 

  9. Storstein A, Monstad SE, Nakkestad HL, Husebye ES, Vedeler CA (2004) Paraneoplastic antibodies against HuD detected by a sensitive radiobinding assay. J Neurol 251:197–203

    Article  PubMed  CAS  Google Scholar 

  10. Monstad SE, Drivsholm L, Storstein A, Aarseth JH, Haugen M, Lang B, Vincent A, Vedeler CA (2004) Hu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer. J Clin Oncol 22:795–800

    Article  PubMed  CAS  Google Scholar 

  11. Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, Graus F (2003) Spectrum of paraneoplastic neurolgical disorders in women with breast and gynecologic cancer. Medicine 82:216–223

    Article  PubMed  Google Scholar 

  12. Pittock SJ, Kryzer TJ, Lennon VA (2004) Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol 56:715–719

    Article  PubMed  CAS  Google Scholar 

  13. Darnell JC, Albert ML, Darnell RB (2000) Cdr2, a target antigen of naturally occuring human tumor immunity, is widely expressed in gynecological tumors. Cancer Res 60:2136–2139

    PubMed  CAS  Google Scholar 

  14. Dalmau J, Furneaux HM, Cordon-Cardo C, Posner JB (1992) The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. Am J Pathol 141:881–886

    PubMed  CAS  Google Scholar 

  15. Buckanovich RJ, Yang YYL, Darnell RB (1996) The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci 16:1114–1122

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Mette Haugen, Kibret Mazengia and Cecilie Totland for technical help. This study was supported by grants from the University of Bergen and Helse Vest.

Author information

Authors and Affiliations

  1. Department of Neurology, Haukeland University Hospital, Bergen, Norway

    Anette Knudsen, Sissel E. Monstad, Jan H. Aarseth & Christian A. Vedeler

  2. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Anette Knudsen, Sissel E. Monstad, Jan H. Aarseth & Christian A. Vedeler

  3. Department of Gynecologic Oncology, National Cancer Hospital, Oslo, Norway

    Anne Dørum

  4. Department of Oncology, Haukeland University Hospital, Bergen, Norway

    Per E. Lønning

  5. Institute of Internal Medicine, University of Bergen, Bergen, Norway

    Per E. Lønning

  6. Department of Gynecology and Obstetrics, Haukeland University Hospital, Bergen, Norway

    Helga B. Salvesen

  7. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Helga B. Salvesen

  8. Department of Oncology and Hematology, Storstrømmens sygehus, Næstved, Denmark

    Lars Drivsholm

Authors
  1. Anette Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sissel E. Monstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne Dørum
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Per E. Lønning
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Helga B. Salvesen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Lars Drivsholm
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jan H. Aarseth
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christian A. Vedeler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anette Knudsen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knudsen, A., Monstad, S.E., Dørum, A. et al. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunol Immunother 55, 1280–1284 (2006). https://doi.org/10.1007/s00262-006-0121-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-006-0121-2

Keywords

Search

Navigation